GF01141333
钌
Ruthenium, microfoil, disks, 10mm, thinness 0.1μm, specific density 122μg/cm2, permanent mylar 3.5μm support, 99.9%
别名:
Ruthenium, RU004500
方案
≥99.9%
表单
foil
制造商/商品名称
Goodfellow 011-413-33
电阻率
7.1 μΩ-cm, 0°C
直径× 厚度
10 mm × 0.1 μm
沸点
3900 °C (lit.)
mp
2310 °C (lit.)
密度
12.45 g/cm3 (lit.)
SMILES字符串
[Ru]
InChI
1S/Ru
InChI key
KJTLSVCANCCWHF-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
For updated SDS information please visit www.goodfellow.com.
法律信息
Product of Goodfellow
储存分类代码
13 - Non Combustible Solids
WGK
nwg
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
Nicole L Fry et al.
Accounts of chemical research, 44(4), 289-298 (2011-03-03)
Nitric oxide (NO) can induce apoptosis (programmed cell death) at micromolar or higher doses. Although cell death via NO-induced apoptosis has been studied quite extensively, the targeted delivery of such doses of NO to infected or malignant tissues has not
Lutz Ackermann et al.
Topics in current chemistry, 292, 211-229 (2010-01-01)
Stoichiometric cycloruthenation reactions of substrates containing Lewis-basic functionalities set the stage for efficient ruthenium-catalyzed C-H bond functionalization reactions. Thereby, selective addition reactions of C-H bonds across alkenes or alkynes enabled atom-economical synthesis of substituted arenes. More recently, ruthenium-catalyzed direct arylation
E Tfouni et al.
Current medicinal chemistry, 17(31), 3643-3657 (2010-09-18)
The discovery of the involvement of nitric oxide (NO) in several physiological and pathophysiological processes launched a spectacular increase in studies in areas such as chemistry, biochemistry, and pharmacology. As a consequence, the development of NO donors or scavengers for
Aviva Levina et al.
Metallomics : integrated biometal science, 1(6), 458-470 (2009-11-01)
Interest in Ru anticancer drugs has been growing rapidly since NAMI-A ((ImH(+))[Ru(III)Cl(4)(Im)(S-dmso)], where Im = imidazole and S-dmso = S-bound dimethylsulfoxide) or KP1019 ((IndH(+))[Ru(III)Cl(4)(Ind)(2)], where Ind = indazole) have successfully completed phase I clinical trials and an array of other
A Bergamo et al.
Journal of inorganic biochemistry, 106(1), 90-99 (2011-11-25)
The study of metal complexes for the treatment of cancer diseases has resulted in the identification of some unique properties of ruthenium-based compounds. Among these inorganic-based agents, two of them, namely the ruthenium(III) drugs NAMI-A and KP1019 have undertaken with
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持